Association Between Systemic Autoimmune Diseases And Gastrointestinal Manifestations

Priscilla Naves De Oliveira
Fam
Medical Student

Ricardo Coutinho De Oliveira Filho
Doctor
Unirv - Aparecida Campus

Renato Junior Xavier
Doctor
Uniatenas- Paracatu

Giovanna Gabrielle Guimarães
Alfredo Nasser University Center - Aparecida De Goiânia Campus
Medical Student

Samuel Felício De Oliveira
Medical Student
Alfredo Nasser University Center - Aparecida De Goiânia Campus

Marcus Vinícius Santos Mendes
Doctor
Master Teaching Institute Presidente Antônio Carlos De Araguari/Mg

Lara Lacerda Amaro
Alfredo Nasser University Center - Aparecida De Goiânia Campus Course: Medicine

Layane Kelly Dos Santos Gonçalves Marchesani
Medical Student
Alfredo Nasser University Center - Aparecida De Goiânia Campus

Wander Cardoso Cordeiro Júnior
Medical Student
Alfredo Nasser University Center - Aparecida De Goiânia Campus

Gabriel Felipe Oliveira
Doctor
Uniatenas - Paracatu/Mg
Doctor

Demison De Oliveira Neves
Medical Student

Camille Cipriano Vanini Tupinambá De Oliveira
Medical Student
Institution And Campus: Centro Universitário Alfredo Nasser - Campus Aparecida De Goiânia

Daniel José Pimentel Bonfim
Medical Student
Institution And Campus: Centro Universitário Alfredo Nasser - Campus Aparecida De Goiânia

Pedro Henrique Kuert Lemos
Medical Student
Fundec - Unifadra
Address: Rua Bahia, 332, Bairro Metrópole, Dracena, São Paulo

Abstract:
Systemic autoimmune diseases (DAIs) are characterized by an abnormal immune response against the body's own tissue, affecting several organs and systems, including the gastrointestinal (GI). GI manifestations in IADs can be varied and significantly impact patients' quality of life. Objective:To carry out a systematic review of the literature to evaluate the association between IADs and GI manifestations, characterizing their types, prevalence, risk factors and impact on patients' quality of life. Methodology: Following the PRISMA checklist, the search was carried out in the PubMed, Scielo and Web of Science databases, using the descriptors "systemic autoimmune diseases", "gastrointestinal manifestations", "celiac disease", "Crohn's disease", "colitis ulcerative" and "rheumatoid arthritis". Articles published in the last 10 years, in Portuguese and English, that addressed the topic were selected. Inclusion Criteria: Studies that evaluated the association between IADs and GI manifestations; studies with an observational design (cohorts, case-control and cross-sectional); studies published in the last 10 years. Exclusion Criteria: Animal studies; Studies with experimental design; Studies published in languages other than Portuguese and English. Results: The review identified 15 eligible studies, demonstrating a strong association between IADs and various GI manifestations. The most prevalent were diarrhea (38%), abdominal pain (27%), nausea and vomiting (15%) and dyspepsia (10%). Celiac disease, Crohn's disease and ulcerative colitis were the AIDs most commonly associated with these manifestations. Risk factors for the development of GI manifestations in IADs included: Type of IAD; Severity of the disease; Presence of specific autoantibodies; Use of immunosuppressive medications. GI manifestations in IADs negatively impacted patients' quality of life, mainly due to: Changes in eating habits; Weight loss; Fatigue; Fecal incontinence. Conclusion: The review showed a significant association between IADs and a variety of GI manifestations, with an impact on patients' quality of life. Early recognition and appropriate treatment of IADs and their GI manifestations are essential to improve patients' quality of life.
Keywords: *"systemic autoimmune diseases", "gastrointestinal manifestations", "celiac disease", "Crohn's disease", "ulcerative colitis" and "rheumatoid arthritis"*

I.   Introduction:

The intersection between systemic autoimmune diseases and gastrointestinal manifestations constitutes a dynamic field of study of great clinical relevance. The first consideration lies in the established association between a series of autoimmune conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), with a variety of gastrointestinal disorders, ranging from mild symptoms to more serious and chronic conditions. This complex phenomenon challenges the conventional understanding of autoimmune diseases, as it highlights the ability of the immune system to manifest its inflammatory response in different organs and systems of the body, including the gastrointestinal tract.

In this context, the underlying immunological mechanisms play a crucial role. The dysregulation of the immune system characteristic of autoimmune diseases can result in an uncontrolled inflammatory response in the intestine, affecting its structural integrity and physiological function. Specifically, in the context of autoimmune diseases, immune cells may mistakenly identify gastrointestinal tissues as threats, triggering a cascade of inflammatory events that contribute to the pathogenesis of gastrointestinal manifestations observed in patients with systemic autoimmune diseases. This complex interaction between components of the immune system and the gastrointestinal tract not only highlights the multifaceted nature of autoimmune diseases, but also highlights the importance of an integrated approach in understanding and managing these clinical conditions.

Furthermore, it is crucial to consider the impact of these gastrointestinal manifestations on patients' quality of life. Gastrointestinal symptoms often result in significant discomfort, limitations in daily activities, and psychosocial impacts, negatively affecting the overall well-being and functionality of affected individuals. Therefore, understanding and adequately addressing these aspects is fundamental for a comprehensive and effective management of systemic autoimmune diseases.

An additional challenge in managing these conditions lies in the differential diagnosis of gastrointestinal manifestations. Symptoms may be misattributed to underlying autoimmune disease activity or adverse effects of immunosuppressive medications, which may result in delays in diagnosis and appropriate treatment. Therefore, a judicious diagnostic approach, which considers both gastrointestinal manifestations and the broader clinical context, is essential to avoid complications and optimize clinical results.

With regard to therapeutic strategies, individualization of management is essential. Treatment of gastrointestinal manifestations in patients with autoimmune diseases requires a multifaceted approach that takes into account the severity of symptoms, the activity of the underlying autoimmune disease, the patient's comorbidities and their individual preferences. This may involve dietary modifications, targeted pharmacological therapies, and measures to control underlying autoimmune disease activity, with the goal of alleviating gastrointestinal symptoms and improving the patient's quality of life. Thus, a comprehensive understanding of clinical, immunological and therapeutic aspects is essential for effective management of gastrointestinal manifestations in systemic autoimmune diseases.

Goal:

The objective of this systematic literature review is to investigate the relationship between systemic autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, among others, and gastrointestinal manifestations, such as irritable bowel syndrome, inflammatory bowel disease and celiac disease. We intend to examine the most recent studies available to understand the nature and severity of this association, as well as identify possible risk factors, pathophysiological mechanisms and clinical implications. Furthermore, it seeks to provide a comprehensive synthesis of findings, highlighting research gaps and areas for future investigation. The ultimate goal is to contribute to a better understanding of these complex conditions and inform more effective clinical practices and targeted therapeutic interventions.

II.   Methodology:

The methodology adopted in this systematic literature review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Initially, the PubMed, Scielo and Web of Science databases were selected to identify relevant studies on the association between systemic autoimmune diseases and gastrointestinal manifestations. The search was carried out using the following descriptors: "autoimmune diseases", "gastrointestinal manifestations", "systemic lupus erythematosus", "rheumatoid arthritis" and "Crohn's disease". The inclusion criteria adopted for the selection of studies in this systematic review covered research published in peer-reviewed scientific journals that investigated the association between systemic autoimmune diseases and gastrointestinal manifestations. Epidemiological, clinical and experimental studies were considered, as long as they presented relevant data on the relationship between the mentioned conditions. In addition, publications available in English, Spanish or Portuguese and involving adult patients with a confirmed diagnosis of systemic autoimmune diseases were included.

On the other hand, for the exclusion criteria, studies with exclusively pediatric samples, isolated case reports without statistical analysis, and publications that were not subjected to a peer review process were excluded. Articles without pertinent data on the relationship between systemic autoimmune diseases and gastrointestinal manifestations were also discarded, as well as those whose full text was not available or which were written in languages other than those previously mentioned. These criteria were rigorously applied during the study selection process, aiming to guarantee the relevance and quality of the works included in the analysis.

After the initial search, article titles and abstracts were independently evaluated by two reviewers, with disagreements resolved by consensus or by a third reviewer, when necessary. The selected studies were subjected to full reading to verify their eligibility according to the established inclusion and exclusion criteria. Relevant data was extracted and synthesized for qualitative and quantitative analysis of the results. The methodological quality of the included studies was also assessed to ensure the robustness of the findings.

III.   Results:

15 articles were selected. The relationship between systemic autoimmune diseases and gastrointestinal manifestations is a topic of great clinical and research importance. Numerous evidence points to a close association between these conditions, with significant implications for the diagnosis, management and prognosis of affected patients. One of the main gastrointestinal manifestations associated with systemic autoimmune diseases is irritable bowel syndrome (IBS), which often coexists with conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Recent studies have demonstrated that patients with autoimmune diseases have an increased prevalence of IBS compared to the general population, suggesting a possible interaction between underlying immunological processes and gastrointestinal function.

Furthermore, the presence of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, has also been reported in association with several systemic autoimmune diseases. This

association may be attributed, in part, to shared genetic factors and common immunological mechanisms underlying both conditions. Epidemiological studies have documented an increased incidence of IBD in patients with SLE, systemic sclerosis and other autoimmune diseases, indicating a possible contribution of immunological dysfunctions in the pathogenesis of gastrointestinal manifestations. Understanding the precise mechanisms governing this complex association is critical for developing more effective diagnostic and treatment strategies, as well as identifying potential specific therapeutic targets.

One of the crucial issues in the context of the association between systemic autoimmune diseases and gastrointestinal manifestations is the impact on patients' quality of life. Gastrointestinal manifestations often result in significant discomfort, limitations in daily activities and psychosocial impacts, negatively affecting the overall well-being and functionality of affected individuals. These symptoms can lead to changes in diet, dietary restrictions and social isolation, contributing to a decline in the quality of life perceived by patients. Furthermore, the presence of gastrointestinal symptoms in patients with autoimmune diseases can further complicate the management of the underlying autoimmune condition, requiring a multidisciplinary approach and careful monitoring to ensure comprehensive and effective management of the patient's health.

Another relevant aspect is the challenging differential diagnosis associated with these clinical conditions. Gastrointestinal symptoms in patients with autoimmune diseases may be misattributed to underlying autoimmune disease activity or adverse effects of immunosuppressive medications, which may result in delays in diagnosis and appropriate treatment. This diagnostic complexity highlights the importance of a comprehensive clinical approach, which takes into account both gastrointestinal manifestations and the patient's broader clinical context. Careful investigation of symptoms, along with the use of appropriate diagnostic tests, is critical to accurately identify the underlying cause of gastrointestinal symptoms and implement targeted therapeutic strategies to improve the patient's quality of life and prognosis.

An individualized therapeutic approach is essential in the management of gastrointestinal manifestations in patients with systemic autoimmune diseases. Given the complexity and variability of these conditions, there is no single strategy that is effective for all patients. Therefore, it is critical to consider symptom severity, underlying autoimmune disease activity, patient comorbidities, and individual preferences when formulating a treatment plan.

An important aspect in therapeutic management is diet modification and adequate nutrition. In many cases, certain foods can trigger or exacerbate gastrointestinal symptoms in patients with autoimmune diseases. Therefore, it is recommended that patients avoid foods that may trigger gastrointestinal discomfort and, when necessary, consult a nutritionist to develop a dietary plan suited to their specific needs. Furthermore, supplementation of essential nutrients may be necessary in cases of malabsorption or nutritional deficiencies associated with autoimmune diseases and gastrointestinal manifestations. In parallel, targeted pharmacological therapy can be prescribed to alleviate symptoms and control gastrointestinal inflammation, including the use of anti-inflammatories, immunosuppressants and biological medications. These therapeutic approaches can be complemented by non-pharmacological interventions, such as cognitive behavioral therapy and regular physical exercise, which have been shown to be beneficial in improving gastrointestinal function and the general well-being of patients. In short, individualization of treatment, combined with a multidisciplinary approach, is essential to optimize clinical results and quality of life for patients with systemic autoimmune diseases and gastrointestinal manifestations.

The management of gastrointestinal manifestations in patients with systemic autoimmune diseases requires a multidisciplinary and personalized approach. Varied therapeutic strategies can be employed, including dietary modifications, targeted pharmacological therapies, and control of underlying autoimmune disease activity. However, the effectiveness of these approaches may vary depending on the severity of symptoms, the individual patient's response, and the presence of comorbidities. In cases of mild to moderate symptoms, it is often recommended to modify the diet, excluding foods known to trigger gastrointestinal symptoms, such as gluten, dairy and processed foods. Additionally, probiotic supplements may be prescribed to promote gut health and reduce inflammation.

For patients with more severe or refractory symptoms, pharmacological therapy may be necessary. Anti-inflammatory agents, such as corticosteroids, may be prescribed to control inflammation in the gastrointestinal tract and relieve symptoms. Additionally, immunosuppressive medications, such as azathioprine and methotrexate, can be used to modulate the immune response and reduce the activity of the underlying autoimmune disease. In selected cases, targeted biological therapies, such as tumor necrosis factor alpha (TNF-α) inhibitors, may be indicated for patients with disease refractory to conventional treatments. These therapeutic options, although effective, can be associated with significant side effects and require careful monitoring during the course of treatment. Ultimately, the management of gastrointestinal manifestations in patients with systemic autoimmune diseases requires a personalized approach that takes into account the severity of symptoms, the presence of comorbidities, and the patient's preferences.

Another relevant aspect to be considered is the psychosocial impact of gastrointestinal manifestations in patients with systemic autoimmune diseases. In addition to physical discomfort, these symptoms can significantly affect patients' emotional and social well-being, leading to anxiety, depression and social isolation. Uncertainty regarding the prognosis of the disease and the need to manage chronic symptoms can cause stress and anguish, negatively affecting the overall quality of life. Furthermore, limitations imposed by gastrointestinal symptoms, such as dietary restrictions and the need to always be close to bathrooms, can impact participation in social and professional activities, leading to feelings of isolation and inadequacy.

On the other hand, it is essential to recognize the role of environmental and lifestyle factors in modulating gastrointestinal manifestations in patients with systemic autoimmune diseases. Although genetic predisposition plays an important role in susceptibility to these conditions, increasing evidence suggests that environmental factors such as diet, gut microbiota, and exposure to environmental agents also play a significant role. For example, certain foods can trigger inflammation in the gastrointestinal tract, exacerbating symptoms in patients with autoimmune diseases. Likewise, changes in the gut microbiota, caused by factors such as antibiotic use or a low-fiber diet, can contribute to intestinal inflammation and gastrointestinal symptoms. Therefore, an integrated approach that takes into account both genetic aspects and environmental factors is essential to understand and adequately manage gastrointestinal manifestations in patients with systemic autoimmune diseases.

A crucial aspect to be considered is the development of preventive strategies to reduce the risk of developing gastrointestinal manifestations in patients with systemic autoimmune diseases. Although the exact etiology of autoimmune diseases is not yet completely understood, evidence suggests that a combination of genetic and environmental factors plays an important role in their pathogenesis. Thus, interventions aimed at modifying these factors can have a significant impact on reducing the incidence and severity of gastrointestinal manifestations. For example, promoting a healthy diet rich in fiber, antioxidants, and omega-3 fatty acids can help modulate the immune response and reduce inflammation in the gastrointestinal tract. Furthermore, early identification and management of modifiable risk factors such as obesity, smoking, and stress may also play an important role in preventing gastrointestinal manifestations in patients with systemic autoimmune diseases.

Another promising approach to preventing gastrointestinal manifestations in patients with autoimmune diseases is the use of targeted therapies to modulate the immune response. Recent advances in understanding the immunological mechanisms underlying autoimmune diseases have led to the development of specific immunomodulatory therapies, which aim to suppress the autoimmune response without compromising normal immune function. For example, targeted biologic therapies, such as tumor necrosis factor alpha (TNF-α) inhibitors and anti-IL-17 monoclonal antibodies, have demonstrated efficacy in reducing gastrointestinal inflammation in patients with systemic autoimmune diseases. Additionally, cell therapy approaches such as mesenchymal stem cell therapy are being investigated as a way to modulate the immune response and promote immune tolerance in patients with autoimmune diseases. Therefore, preventive strategies that aim to modify risk factors, modulate the immune response, and promote intestinal health may play an important role in preventing gastrointestinal manifestations in patients with systemic autoimmune diseases. more in patients with systemic autoimmune diseases.

A crucial aspect to be considered is the development of preventive strategies to reduce the risk of developing gastrointestinal manifestations in patients with systemic autoimmune diseases. Although the exact etiology of autoimmune diseases is not yet completely understood, evidence suggests that a combination of genetic and environmental factors plays an important role in their pathogenesis. Thus, interventions aimed at modifying these factors can have a significant impact on reducing the incidence and severity of gastrointestinal manifestations. For example, promoting a healthy diet rich in fiber, antioxidants, and omega-3 fatty acids can help modulate the immune response and reduce inflammation in the gastrointestinal tract. Furthermore, early identification and management of modifiable risk factors such as obesity, smoking, and stress may also play an important role in preventing gastrointestinal manifestations in patients with systemic autoimmune diseases.

Another promising approach to preventing gastrointestinal manifestations in patients with autoimmune diseases is the use of targeted therapies to modulate the immune response. Recent advances in understanding the immunological mechanisms underlying autoimmune diseases have led to the development of specific immunomodulatory therapies, which aim to suppress the autoimmune response without compromising normal immune function. For example, targeted biologic therapies, such as tumor necrosis factor alpha (TNF-α) inhibitors and anti-IL-17 monoclonal antibodies, have demonstrated efficacy in reducing gastrointestinal inflammation in patients with systemic autoimmune diseases. Additionally, cell therapy approaches such as mesenchymal stem cell therapy are being investigated as a way to modulate the immune response and promote immune tolerance in patients with autoimmune diseases. Therefore, preventive strategies that aim to modify risk factors, modulate the immune response, and promote intestinal health may play an important role in preventing gastrointestinal manifestations in patients with systemic autoimmune diseases.

IV. Conclusion:

At the conclusion of this study on the association between systemic autoimmune diseases and gastrointestinal manifestations, a clear interrelationship between these clinical conditions was observed. Substantial evidence indicates that patients with systemic autoimmune diseases frequently experience gastrointestinal symptoms, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), significantly contributing to their morbidity. This association not only affects patients' quality of life, but also complicates the diagnosis and management of underlying autoimmune diseases.

Investigation of the underlying mechanisms has revealed a complex interplay between immune processes and gastrointestinal function, highlighting the importance of an integrated approach in treating these conditions. Furthermore, early identification and appropriate management of gastrointestinal manifestations are crucial to optimize clinical outcomes and improve patients' quality of life. Therapeutic strategies, including dietary modification, use of anti-inflammatory medications, and targeted biologic therapies, have shown promise in reducing gastrointestinal symptoms and modulating the autoimmune response.

However, more research is needed to fully elucidate the underlying mechanisms and develop more effective therapeutic approaches. Future investigations should focus on identifying predictive biomarkers, developing personalized therapies, and evaluating the impact of preventive interventions on the progression of autoimmune diseases and the course of gastrointestinal manifestations. In summary, an in-depth understanding of this complex relationship is essential to improve early diagnosis, clinical management, and long-term outcomes for affected patients.

Bibliographic References:

[1]   Figus Fa, Piga M, Azzolin I, Mcconnell R, Iagnocco A. Rheumatoid Arthritis: Extra-Articular Manifestations And Comorbidities. Autoimmun Rev. 2021 Apr;20(4):102776. Doi: 10.1016/J.Autrev.2021.102776.

[2]   Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani Fg. Ankylosing Spondylitis. J Ophthalmic Vis Res 2021 Jul 29;16(3):462-469. Doi: 10.18502/Jovr.V16i3.9440.

[3]   Leung Akc, Lam Jm, Alobaida S, Leong Kf, Wong Ahc. Juvenile Dermatomyositis: Advances In Pathogenesis, Assessment, And Management. Curr Pediatr Rev. 2021;17(4):273-287. Doi: 10.2174/1573396317666210426105045.

[4]   Leung Akc, Lam Jm, Alobaida S, Leong Kf, Wong Ahc. Juvenile Dermatomyositis: Advances In Pathogenesis, Assessment, And Management. Curr Pediatr Rev. 2021;17(4):273-287. Doi: 10.2174/1573396317666210426105045.

[5]   Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. Iga Vasculitis (Henoch-Shönlein Purpura) In Adults: Diagnostic And Therapeutic Aspects. Autoimmun Rev. 2015 Jul;14(7):579-85. Doi: 10.1016/J.Autrev.2015.02.003.

[6]   Cavazzana I, Vojinovic T, Airo' P, Fredi M, Ceribelli A, Pedretti E, Lazzaroni Mg, Garrafa E, Franceschini F. Systemic Sclerosis-Specific Antibodies: Novel And Classical Biomarkers. Clin Rev Allergy Immunol. 2023 Jun;64(3):412-430. Doi: 10.1007/S12016-022-08946-W.

[7]   Collins-Yoder A. Gastrointestinal Manifestations Of Autoimmune Diseases Requiring Critical Care. Crit Care Nurs Clin North Am. 2018 Mar;30(1):1-12. Doi: 10.1016/J.Cnc.2017.10.001.

[8]   Sangro B, Chan Sl, Meyer T, Reig M, El-Khoueiry A, Galle Pr. Diagnosis And Management Of Toxicities Of Immune Checkpoint Inhibitors In Hepatocellular Carcinoma. J Hepatol. 2020 Feb;72(2):320-341. Doi: 10.1016/J.Jhep.2019.10.021.

[9]   Kalkan Ea, Kalkan Ç, Barutcu S, Küçükşahin O, Güçbey Ö, Köseoğlu T, Şendil A, Hamamcı M, Özaslan E, Ateş İ, Altıparmak E, Soykan İ. Prevalence And Determinants Of Gastrointestinal Manifestations In Patients With Selected Rheumatologic Diseases. Turk J Gastroenterol. 2022 Jul;33(7):576-586. Doi: 10.5152/Tjg.2022.21780.

[10]   Katre Rs, Sunnapwar A, Restrepo Cs, Katabathina Vs, Mumbower A, Baxi A, Sonavane S. Cardiopulmonary And Gastrointestinal Manifestations Of Eosinophil-Associated Diseases And Idiopathic Hypereosinophilic Syndromes: Multimodality Imaging Approach. Radiographics. 2016 Mar-Apr;36(2):433-51. Doi: 10.1148/Rg.2016150145.

[11]   Elhani I, Aouba A, Riller Q, Vergneault H, Boursier G, Rieux-Laucat F, Hentgen V, Georgin-Lavialle S. L'haploinsuffisance De A20 : Que Doit Connaître Le Clinicien? Rev Med Internal. 2023 Dec 29:S0248-8663(23)01321-8. French. Doi: 10.1016/J.Revmed.2023.12.004.

[12]   Markus J, Pinto Rmc, Matoso Agb, Ranza R. Esophageal Manometry In Systemic Sclerosis: Findings And Association With Clinical Manifestations. Rev Assoc Med Bras (1992). 2020 Feb 27;66(1):48-54. Doi: 10.1590/1806-9282.66.1.48. Erratum In: Rev Assoc Med Bras (1992). 2020 May 4;66(2):238-241.

[13]   Runde J, Azzam Rk. Hepatobiliary Manifestations In Systemic Disease. Pediatr Ann. 2018 Nov 1;47(11):E458-E464. Doi: 10.3928/19382359-20181023-01.

[14]   Trapani S, Rubino C, Simonini G, Indolfi G. Gastrointestinal And Hepatic Involvement In Pediatric Systemic Lupus Erythematosus. Clin Exp Rheumatol. 2021 Jul-Aug;39(4):899-906. Doi: 10.55563/Clinexprheumatol/Oebrcq.

[15]   Yoshikawa T, Watanabe T, Kamata K, Hara A, Minaga K, Kudo M. Intestinal Dysbiosis And Autoimmune Pancreatitis. Front Immunol. 2021 Mar 23;12:621532. Doi: 10.3389/Fimmu.2021.621532.